MX2019005140A - Exosomas y usos de los mismos en enfermedades del cerebro. - Google Patents

Exosomas y usos de los mismos en enfermedades del cerebro.

Info

Publication number
MX2019005140A
MX2019005140A MX2019005140A MX2019005140A MX2019005140A MX 2019005140 A MX2019005140 A MX 2019005140A MX 2019005140 A MX2019005140 A MX 2019005140A MX 2019005140 A MX2019005140 A MX 2019005140A MX 2019005140 A MX2019005140 A MX 2019005140A
Authority
MX
Mexico
Prior art keywords
exosomes
brain
disease
attendant
medicaments
Prior art date
Application number
MX2019005140A
Other languages
English (en)
Inventor
J Prockop Darwin
Qianfa Long
UPADHYA Dinesh
HATTIANGADY Bharathi
Shetty Ashok
Kim Dong-Ki
Original Assignee
J Prockop Darwin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Prockop Darwin filed Critical J Prockop Darwin
Publication of MX2019005140A publication Critical patent/MX2019005140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen medicamentos y métodos para inhibir la inflamación cerebral y la pérdida de memoria cognitiva por enfermedad y daño cerebral en un animal. El estado epiléptico, apoplejía y enfermedad de Alzheimer son patologías particulares que se tratan empleando preparaciones farmacéuticamente aceptables de los exosomas Al. Las preparaciones comprenden una población enriquecida de exosomas Al, tal como exosomas derivados de medio de cultivo de células madre mesenquimales. Los medicamentos y métodos para inhibir el reconocimiento de patrones y/o deterioro de memoria por un evento de lesión cerebral o enfermedad cerebral degenerativa también se describen, que comprenden administrar una preparación farmacéuticamente aceptable de exosomas, particularmente exosomas Al, que son CD9- y que previenen la elevación de citocinas pro-inflamatorias por lesión cerebral o enfermedad.
MX2019005140A 2016-11-02 2017-11-02 Exosomas y usos de los mismos en enfermedades del cerebro. MX2019005140A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416638P 2016-11-02 2016-11-02
PCT/US2017/059787 WO2018085587A1 (en) 2016-11-02 2017-11-02 Exosomes and uses thereof in diseases of the brain

Publications (1)

Publication Number Publication Date
MX2019005140A true MX2019005140A (es) 2020-01-20

Family

ID=62076165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005140A MX2019005140A (es) 2016-11-02 2017-11-02 Exosomas y usos de los mismos en enfermedades del cerebro.

Country Status (4)

Country Link
US (1) US20220175842A1 (es)
EP (1) EP3534918A4 (es)
MX (1) MX2019005140A (es)
WO (1) WO2018085587A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180327714A1 (en) 2015-11-18 2018-11-15 University Of Georgia Research Foundation, Inc. Neural cell extracellular vessicles
WO2020215158A1 (en) * 2019-04-26 2020-10-29 Braun Janice E A Method and vehicle for delivering agents across the blood-brain barrier
CN113082058A (zh) * 2021-03-19 2021-07-09 瑞太生物科技(沈阳)有限公司 一种细胞来源的外泌体在制备治疗阿尔茨海默病生物制剂中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013039000A1 (ja) * 2011-09-13 2015-03-26 孝広 落谷 アルツハイマー病の予防または治療のための医薬品
US9919011B2 (en) * 2014-03-18 2018-03-20 Samsung Life Public Welfare Foundation Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome
EP3145493B1 (en) * 2014-05-18 2022-07-27 Children's Medical Center Corporation Methods and compositions relating to exosomes
EP3288571A4 (en) * 2015-04-28 2018-12-19 The Texas A&M University System Scalable production of standardized extracellular vesicles, extracellular vesicle preparations and uses thereof

Also Published As

Publication number Publication date
US20220175842A1 (en) 2022-06-09
EP3534918A1 (en) 2019-09-11
EP3534918A4 (en) 2020-07-22
WO2018085587A1 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
EP4104867A3 (en) Compositions and methods for treatment of central nervous system diseases
WO2017218949A3 (en) Peptidomimetic macrocycles and uses thereof
MX2018001196A (es) Compuesto derivado de amida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6 y composición farmacéutica que lo contiene.
MX2019005140A (es) Exosomas y usos de los mismos en enfermedades del cerebro.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MY187358A (en) Modified release orally administered amino acid formulations
MX2019002518A (es) Metodos y vectores para el tratamiento de trastornos del snc.
MX2018010395A (es) Formulaciones topicas que contienen cliclosporina y usos de las mismas.
MX2017013852A (es) Produccion escalable de vesiculas extracelulares estandarizadas, preparaciones de vesiculas extracelular y usos de estos.
EP4338804A3 (en) Epinephrine spray formulations
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2021002321A (es) Nuevos metodos.
MX2020008359A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
NZ759173A (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
MX2022004759A (es) Métodos y composiciones para tratar enfermedades y trastornos hepáticos.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
WO2021222476A3 (en) High efficiency gene delivery system